News
AMSilk Relocate Offices to Support Expansion Plans
The purpose-built offices will support its production of game-changing…
Neuraxpharm launches European campaign to increase awareness of medical cannabis
Neuraxpharm launches European campaign to increase awareness…
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
AMSTERDAM, THE NETHERLANDS October 18th, 2022 — Synaffix B.V.…
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
Non-dilutive capital finances planned launch of ensifentrine…
ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia
Inglewood, California, October 17th 2022 – ImaginAb, Inc.,…
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona…
Muna Therapeutics Awarded $4.9M Grant from The Michael J. Fox Foundation for Parkinson’s Research Supports Development of Disease Modifying Therapy for Parkinson’s Disease
Copenhagen, Denmark and Boston, US, 11th October 2022 – Muna…
Novo Nordisk Foundation establishes fellowships with four top international universities
The Novo Nordisk Foundation is expanding and extending its Interdisciplinary…
Novo Nordisk Foundation and World Food Programme launch partnership to improve food systems in Rwanda and Uganda
Copenhagen – The Novo Nordisk Foundation and the United Nations…
Panaxia and Neuraxpharm to enter new medical cannabis markets in Europe
Both companies will expand their cooperation through the distribution…
Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors
Financing led by Brandon Capital, Forbion and Atlas Venture
…
Destiny Pharma plc – Notice of R&D Update Meeting
Brighton, United Kingdom – 22 September 2022 – Destiny…
Novo Nordisk Foundation: Major investment for developing Denmark’s first fully functional quantum computer
Denmark’s first fully functional generally applicable quantum…
World-class translational project enters the Bio Studio program as part of collaboration with Imperial College London
BioInnovation Institute (BII) announces that it has entered a…
Ariceum Therapeutics Q4 2022 Investor and Scientific Conference
BERLIN, 15 September 2022 – Ariceum Therapeutics (Ariceum),…
Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022
AMSTERDAM, NETHERLANDS – 15th September 2022 — Synaffix…
Futura Medical Interim Results for the Six Months ended 30 June 2022
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022
STORM recognised as an innovative early-stage biotechnology company…
Sequana Medical announces H1 2022 results and provides business update
alfapump® – strong interim data / on track to report primary…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
